Rare primary tumors.
Primary cardiac tumor incidence ranges from .02% to 0.1%.
75 percent of primary cardiac tumors are benign.
Nearly 50% of benign cardiac tumors are myxomas.
Benign cardiac tumors include myxomas, lipomas, papillary fibroelastomas and rhabdomyomas.
Cardiac tumors are abnormal growths within the heart or pericardium, classified as either primary, those that originate in the heart, or secondary, like metastatic from other sites.
Primary cardiac tumors are rare, with an incidence of approximately 0.02% in autopsy series, and are further divided into benign (about 75–90%) and malignant (10–25%) types.
The most common benign primary cardiac tumors in adults are myxomas and papillary fibroelastomas, while rhabdomyomas predominate in children.
Myxomas-about 50% of benign tumors.
Usually occurs in the left atrium
Can cause obstruction, embolization, or constitutional symptoms
Typically requires surgical removal
Papillary fibroelastoma is the second most common benign heart tumor.
Often found on heart valves Has a risk of embolization
Rhabdomyoma is most common in infants and children, often associated with tuberous sclerosis.
Papillary fibroelastoma may regress spontaneously.
Lipoma and fibroma are less common benign types.
Malignant primary tumors are most often sarcomas, such as angiosarcoma and rhabdomyosarcoma.
Angiosarcoma is ggressive with poor prognosis and often affects the right atrium
Metastatic cardiac tumors are much more common than primary tumors, occurring 20–30 times more frequently: Usually from lung, breast, melanoma, lymphoma, or kidney cancers
Approximately 95% of malignant primary cardiac tumors are sarcomas, usually angiosarcomas or rhabdomyosarcomas.
The second most common malignant primary cardiac tumor is primary cardiac lymphoma, the incidence of which is increasing.
Risk factors include infection with HIV, Epstein-Barr virus, and organ transplantation.
Cardiac lymphomas have a prediction for the right side of the heart.
These typically result from cancers of the lung, breast, pleura, or hematologic malignancies, and can involve the heart via direct extension, hematogenous spread, or lymphatic routes.
Clinical presentation varies widely and depends on tumor type, size, and location.
Symptoms may include arrhythmias, heart failure, embolic events, chest discomfort, syncope, or sudden cardiac death.
Some cardiac tumors are discovered incidentally during imaging for unrelated reasons.
Diagnosis relies on multimodality imaging, with echocardiography as the first-line tool, supplemented by cardiac MRI, CT, and sometimes PET for further characterization.
Histopathological confirmation is required for definitive diagnosis.
Management:
Benign tumors are often treated with surgical resection, which is usually curative.
Malignant and metastatic tumors require a multidisciplinary approach, including surgery, chemotherapy, radiotherapy, and emerging targeted therapies, but prognosis remains poor for malignant cases.p
Clinical Presentation
Symptoms depend on location and size of the tumor.
Heart failure symptoms Arrhythmias Embolic events (stroke, peripheral embolism) Chest pain or pericardial effusion Constitutional symptoms (fever, weight loss, fatigue) Sometimes found incidentally
Diagnosis
Echocardiography Cardiac MRI for tissue characterization CT scanning Cardiac catheterization in some case Biopsy may be needed for definitive diagnosis
Treatment Benign tumors-Surgical resection when symptomatic or at risk of complications Malignant tumors-Surgery if possible, plus chemotherapy and/or radiation Metastatic tumors-Treatment of underlying cancer, palliative care
The prognosis varies widely depending on tumor type, with benign tumors having excellent outcomes after resection, while malignant primary tumors generally have poor prognosis.
*